The Diagnosis and Management of Gestational Diabetes Mellitus in the Context of the COVID-19 Pandemic
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
The oral glucose tolerance test (OGTT) has, to date, been considered the cornerstone of the diagnosis of gestational diabetes mellitus (GDM). This is despite ongoing national and international disagreement regarding which women require testing, whether “one step” or “two step” testing is optimal, and which glucose thresholds should be used. However, in the context of the current coronavirus disease 2019 (COVID-19) pandemic, widespread anecdotal evidence suggests that both clinicians and pregnant women are increasingly unwilling to recommend or undergo the OGTT. This is based on valid concerns regarding travel, the possible need for two visits, and the time (up to 3 h) spent in the potentially infectious environment of specimen collection centers. Further, a GDM diagnosis generally involves additional health service visits for diabetes education, glucose monitoring review, and fetal ultrasonography, all of which carry exposure risks during a pandemic. In response to these concerns, professional societies from the U.K. (1), Canada (2), and Australia (3) have released urgent statements of advice/guidance for modification of GDM diagnostic pathways during the COVID-19 pandemic. Current GDM guidelines differ in each of these jurisdictions, as do the revised recommendations. All seek to reduce the need for OGTTs, both during pregnancy and in postpartum follow-up. All guidelines support use of an early pregnancy HbA1c ≥41 mmol/mol (5.9%) to identify GDM, though some offer other options. The revised recommendations for standard (24- to 28-week) GDM testing are more divergent. The U.K. currently advocates risk factor–based testing for GDM, and …
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sacks, D. A., Hadden, D. R., Maresh, M., Deerochanawong, C., Dyer, A. R., Metzger, B. E., Lowe, L. P., Coustan, D. R., Hod, M., Oats, J. J. N., et al. (2012) · Diabetes Care · doi:10.2337/dc11-1641 · Cited by 687
Plasma glycated CD59, a novel biomarker for detection of pregnancy-induced glucose intolerance
Ghosh, P., Luque-Fernandez, M. A., Vaidya, A., Ma, D., Sahoo, R., Chorev, M., Zera, C., McElrath, T. F., Williams, M. A., Seely, E. W., et al. (2017) · Diabetes Care · doi:10.2337/dc16-2598 · Cited by 48 · cited 2×
“Validation and regulatory approval of new, nonfastingbiomarkers, ofwhich glycated CD59 (6) is currently themost promising, would be welcomed by both clinicians and pregnant women.”
Background
Cited by
Gestational Diabetes Mellitus—Recent Literature Review
Modzelewski, R., Stefanowicz-Rutkowska, M. M., Matuszewski, W., & Bandurska-Stankiewicz, E. M. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11195736 · Cited by 223
McIntyre, H. D., Gibbons, K. S., Ma, R. C. W., Tam, W. H., Sacks, D. A., Lowe, J., Madsen, L. R., & Catalano, P. M. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108353 · Cited by 81
Laurie, J. G., & McIntyre, H. D. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17249387 · Cited by 65
Self-citationvan Gemert, T. E., Moses, R. G., Pape, A. V., & Morris, G. J. (2020) · Australian and New Zealand Journal of Obstetrics and Gynaecology · doi:10.1111/ajo.13203 · Cited by 40
Self-citation
Metadata
- Authors
- McIntyre, H. D., & Moses, R. G.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2020-05-14
- Volume
- 43
- Issue
- 7
- Pages
- 1433-1434
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W3024018146
- Cited by
- 58
- References
- 2
- FWCI
- 7.07
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.